SCNX News & Events

Scienture provided a commercial update on Arbli oral suspension, the first and only FDA-approved ready-to-use oral liquid formulation of losartan, alongside key market access achievements, financial strengthening initiatives, and near-term outlook-including reaffirming its plan to commercially launch Rezenopy, a life-saving opioid overdose emergency treatment, in the second quarter of 2026. Over the past four months, Scienture has executed a series of commercial, payer and patient-focused initiatives designed to materially expand access to Arbli across retail, institutional, and managed care channels within the approximately $241 million in total annual sales and 72 million prescriptions U.S. losartan market.

Scienture announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 12,514,854 B2, an Orange Book-listable patent covering REZENOPY Nasal Spray 10 mg, effective January 6, 2026, with an expiry date of February 5, 2041. The patent was issued to Summit Biosciences, a subsidiary of Kindeva Drug Delivery L.P. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with Summit in March 2025 for the exclusive U.S. commercialization rights to REZENOPY. Under the terms of the collaboration, Summit will manufacture and commercially supply REZENOPY. Pending certain commercial obligations, Scienture will own the new drug application, NDA, for REZENOPY in its name and be responsible for the sales, marketing and distribution of the product in the U.S. through Scienture's commercial operations infrastructure.

Scienture provided an update on the commercial launch of REZENOPY. As previously disclosed, Scienture, a wholly owned subsidiary of Scienture Holdings, entered into a definitive agreement with Summit Biosciences in March 2025, for the exclusive U.S. commercialization rights to REZENOPY Nasal Spray 10 mg, which received FDA approval on April 19, 2024. "REZENOPY represents a significant advancement in overdose response as the highest-strength naloxone available on the market at 10 mg. It is specifically designed for patients who often require multiple doses of lower-strength naloxone for stabilization in emergency situations," commented Narasimhan Mani, President and co-CEO of Scienture. "By delivering a higher dose of naloxone, REZENOPY is intended to support opioid receptor antagonism and may help address overdose situations where multiple or potent opioids are involved."